Jonathan Sheena Sells 2,700 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.87, for a total value of $293,949.00. Following the transaction, the insider now directly owns 301,808 shares of the company’s stock, valued at approximately $32,857,836.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Sheena also recently made the following trade(s):

• On Tuesday, June 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $109.66, for a total value of $296,082.00.
• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $108.30, for a total value of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $89.55, for a total value of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The stock was sold at an average price of $92.47, for a total value of $2,468,949.00.

Natera Stock Performance

Shares of Natera stock opened at $111.64 on Thursday. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $117.23. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. The business’s fifty day moving average price is $105.70 and its 200 day moving average price is $86.87.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The firm had revenue of $367.70 million for the quarter, compared to analysts’ expectations of $316.31 million. During the same quarter last year, the firm earned ($1.23) earnings per share. The firm’s revenue for the quarter was up 52.1% compared to the same quarter last year. As a group, equities analysts expect that Natera, Inc. will post -2.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. The Goldman Sachs Group lifted their price objective on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. Jefferies Financial Group began coverage on Natera in a research report on Monday, June 3rd. They issued a “buy” rating and a $142.00 price objective for the company. TD Cowen lifted their price objective on Natera from $123.00 to $137.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Finally, BTIG Research lifted their price objective on Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, May 13th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $101.19.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. RiverPark Advisors LLC acquired a new position in shares of Natera during the fourth quarter worth about $27,000. Principal Securities Inc. acquired a new position in shares of Natera during the fourth quarter worth about $32,000. GAMMA Investing LLC lifted its stake in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares in the last quarter. YHB Investment Advisors Inc. acquired a new position in shares of Natera during the first quarter worth about $36,000. Finally, Oliver Lagore Vanvalin Investment Group lifted its stake in shares of Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.